Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

Plant-based diets may help patients with diabetes, heart disease live longer
Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
FDA sees promise in new AI model for heart attack detection
Powerful Medical's advanced algorithm was designed to detect STEMI and STEMI-equivalent patterns in a patient’s ECG results.
Timing is everything: Delaying noncardiac surgery after a heart procedure reduces risks
When patients require subsequent noncardiac surgery after a major heart operation, waiting at least 100 days is one way to limit the risk of an adverse event. Read the full analysis in JACC: Advances.
Abbott makes IVL move as FDA approves new clinical trial
Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.

diet nuts legumes vegetables vegan vegetarian plant-based

Plant-based diets may help patients with diabetes, heart disease live longer

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

Darren K. McGuire, MD, discusses late-breaking data on oral semaglutide

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.

artificial intelligence AI heart cardiology

FDA sees promise in new AI model for heart attack detection

Powerful Medical's advanced algorithm was designed to detect STEMI and STEMI-equivalent patterns in a patient’s ECG results.

Timing is everything: Delaying noncardiac surgery after a heart procedure reduces risks

When patients require subsequent noncardiac surgery after a major heart operation, waiting at least 100 days is one way to limit the risk of an adverse event. Read the full analysis in JACC: Advances.

Abbott makes IVL move as FDA approves new clinical trial

Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.

Cannabis use increases risk of heart attack, stroke in young adults

“Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,” one researcher said. Additional details will be presented at ACC.25 in Chicago.

Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

American College of Cardiology shares new guidance focused on evaluation, management of cardiogenic shock

The new document represents the ACC’s first Concise Clinical Guidance; it was designed to be an easy-to-use reference for keeping track of a complicated topic.